ReviewMaterials (Basel, Switzerland)2026
Zinc Oxide Nanoparticles as Drug Delivery Tools.
Review in Materials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Zinc oxide nanoparticles (ZnO-NPs) have emerged as promising inorganic nanocarriers for drug delivery due to their unique physicochemical properties, pH-responsive biodegradability, high surface area, and intrinsic biological activity. Their dissolution under acidic conditions enables controlled drug release within the tumor microenvironment and intracellular compartments, improving therapeutic selectivity while aiming to reduce off-target exposure. Surface functionalization with polyethylene glycol (PEG), chitosan, hyaluronic acid, and folic acid has further improved nanoparticle stability, prolonged circulation, and promoted receptor-mediated cellular uptake in targeted tissues. Beyond serving as drug carriers, ZnO-NPs exhibit intrinsic anticancer, antimicrobial, and anti-inflammatory activities, primarily through the generation of reactive oxygen species and controlled release of Zn
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.